Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Capehorn

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Obesity Reports|June 29, 2016
Obesity Treatment in the UK Health SystemMatthew S Capehorn, David W Haslam, Richard Welbourn
Advances in Therapy|August 4, 2022
The Potential Role of Digital Health in Obesity CareNigel Hinchliffe, Matthew S Capehorn, Michael Bewick, et al.
Cardiovascular Diabetology|September 2, 2022
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trialsOfri Mosenzon, Matthew S Capehorn, Alessandra De Remigis, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2020
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysisIldiko Lingvay, Matthew S Capehorn, Andrei-Mircea Catarig, et al.
Advances in Therapy|April 22, 2022
Recommendations from a Working Group on Obesity Care Competencies for Healthcare Education in the UK: A Report by the Steering CommitteeMatthew S Capehorn, Nigel Hinchliffe, Deborah Cook, et al.
The Journal of Clinical Endocrinology and Metabolism|April 3, 2019
Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on SemaglutideVivian A Fonseca, Matthew S Capehorn, Satish K Garg, et al.
Diabetes, Obesity & Metabolism|October 15, 2019
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trialsVanita R Aroda, Matthew S Capehorn, Louis Chaykin, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Obesity Reports|June 29, 2016
Obesity Treatment in the UK Health SystemMatthew S Capehorn, David W Haslam, Richard Welbourn
Advances in Therapy|August 4, 2022
The Potential Role of Digital Health in Obesity CareNigel Hinchliffe, Matthew S Capehorn, Michael Bewick, et al.
Cardiovascular Diabetology|September 2, 2022
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trialsOfri Mosenzon, Matthew S Capehorn, Alessandra De Remigis, et al.
The Journal of Clinical Endocrinology and Metabolism|August 23, 2020
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysisIldiko Lingvay, Matthew S Capehorn, Andrei-Mircea Catarig, et al.
Advances in Therapy|April 22, 2022
Recommendations from a Working Group on Obesity Care Competencies for Healthcare Education in the UK: A Report by the Steering CommitteeMatthew S Capehorn, Nigel Hinchliffe, Deborah Cook, et al.
The Journal of Clinical Endocrinology and Metabolism|April 3, 2019
Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on SemaglutideVivian A Fonseca, Matthew S Capehorn, Satish K Garg, et al.
Diabetes, Obesity & Metabolism|October 15, 2019
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trialsVanita R Aroda, Matthew S Capehorn, Louis Chaykin, et al.
Pageof 1